AUTHOR=Kemin Li , Mengpei Zhang , Rutie Yin 

TITLE=Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1035170

DOI=10.3389/fonc.2022.1035170

ISSN=2234-943X

ABSTRACT=<sec><title>Objective</title><p>To investigate the monotherapy for gestational trophoblastic neoplasia (GTN) patients with FIGO/WHO prognostic score of 5–6.</p></sec><sec><title>Methods</title><p>The low-risk GTN patients from 2012 to 2019 were enrolled. The study is a retrospective report to analyze the efficacy and safety of single-agent chemotherapy and combination chemotherapy in patients with a high FIGO/WHO prognostic score of 5–6.</p></sec><sec><title>Results</title><p>75 cases (33.5%) were included. Complete remission was in all patients. Among the 29 cases taking single-agent chemotherapy, 22 cases (75.9%) developed drug resistance. Among the 46 cases taking combination chemotherapy, 7 patients (15.2%) developed drug resistance. There was a statistically significant difference in the drug resistance rate between these two subgroups (P &lt; 0.05), but there was not statistically significant difference in the total number of chemotherapy courses (&lt;2mIU/ml) (P &lt; 0.05).</p></sec><sec><title>Conclusion</title><p>Monotherapy showed remarkable advantages in GTN patients with FIGO/WHO prognostic score of 5–6.</p></sec>